Cardiovascular Risk and Risk Factor Management in Type 2 Diabetes Mellitus:A Population-Based Cohort Study Assessing Sex Disparities by Wright, Alison K et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1161/CIRCULATIONAHA.118.039100
Document Version
Peer reviewed version
Link to publication record in King's Research Portal
Citation for published version (APA):
Wright, A. K., Kontopantelis, E., Emsley, R., Buchan, I. E., Mamas, M. A., Sattar, N., ... Rutter, M. K. (2019).
Cardiovascular Risk and Risk Factor Management in Type 2 Diabetes Mellitus: A Population-Based Cohort
Study Assessing Sex Disparities. Circulation, 139(24), 2742-2753.
https://doi.org/10.1161/CIRCULATIONAHA.118.039100
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 11. Jul. 2020
10.1161/CIRCULATIONAHA.118.039100 
1 
Cardiovascular Risk and Risk Factor Management in Type 2 Diabetes: 
A Population-Based Cohort Study Assessing Sex Disparities 
Running Title: Wright et al.; Sex Disparity in Cardiovascular Risk & Management 
Alison K. Wright, PhD1,2; Evangelos Kontopantelis, PhD3; Richard Emsley, PhD4;  
Iain Buchan, PhD5,6; Mamas A. Mamas, FRCP7; Naveed Sattar, PhD FRCP8;  
Darren M. Ashcroft, PhD1*; Martin K. Rutter, MD FRCP2,9* 
1Centre for Pharmacoepidemiology and Drug Safety, Division of Pharmacy and Optometry, 
School of Health Sciences, University of Manchester, Manchester Academic Health Sciences 
Centre, Manchester, UK; 2Division of Diabetes, Endocrinology and Gastroenterology, School of 
Medical Sciences, University of Manchester, Manchester, UK; 3Division of Population Health, 
Health Services & Primary Care, School of Health Sciences, University of Manchester, 
Manchester, UK; 4Department of Biostatistics & Health Informatics, Institute of Psychiatry, 
Psychology and Neuroscience, King’s College London, London, UK; 5Health eResearch Centre, 
Farr Institute, Division of Informatics, Imaging & Data Sciences, School of Health Sciences, 
University of Manchester, Manchester, UK; 6Department of Public Health and Policy, Institute 
of Population Health Sciences, University of Liverpool, Liverpool, UK; 7Keele Cardiovascular 
Group, Centre for Prognosis Research, Keele University, Stoke-on-Trent, UK; 8Institute of 
Cardiovascular & Medical Sciences, University of Glasgow, Glasgow, UK; 9Manchester 
Diabetes Centre, Manchester University NHS Foundation Trust, Manchester Academic Health 
Sciences Centre, Manchester, UK 
*These authors contributed equally.
Address for Correspondence:  
Alison K. Wright, PhD 
Centre for Pharmacoepidemiology and Drug Safety 
Division of Pharmacy and Optometry 
The University of Manchester, Stopford Building 
Oxford Road, Manchester, M13 9PT, UK 
Tel: +44(0)161 275 8334 
Email: alison.wright@manchester.ac.uk 
D
ow
nloaded from
 http://ahajournals.org by on April 16, 2019
10.1161/CIRCULATIONAHA.118.039100 
2 
Abstract 
 
Background: With recent changes in UK clinical practice for diabetes care, contemporary 
estimates of sex disparities in cardiovascular risk and risk factor management are needed.  
Methods: In this retrospective cohort study, using the Clinical Practice Research Datalink linked 
to hospital and death records for people in England, we identified 79,985 patients with incident 
T2DM between 2006-2013 matched to 386,547 patients without diabetes. Sex-stratified Cox 
models were used to assess cardiovascular risk. 
Results: Compared to women without T2DM, women with T2DM had a higher cardiovascular 
event risk (adjusted HR 1.20 [95% CI 1.12-1.28]) with similar corresponding data in men (HR 
1.12 [1.06-1.19]) leading to a non-significant higher relative risk in women (risk ratio 1.07 [0.98-
1.17]). However, some important sex differences in the management of risk factors were 
observed. Compared to men with T2DM, women with T2DM were more likely to be obese, 
hypertensive and have hypercholesterolaemia but were less likely to be prescribed lipid-lowering 
medication and ACE inhibitors, especially if they had CVD.  
Conclusions: Compared to men developing T2DM, women with T2DM do not have a 
significantly higher relative increase in cardiovascular risk, but ongoing sex disparities in 
prescribing should prompt heightened efforts to improve the standard and equity of diabetes care 
in women and men. 
 
Key Words: sex-specific; cardiovascular disease risk factors; cardiovascular outcomes; type 2 
diabetes mellitus; database 
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Clinical Perspective 
 
What is new? 
• In contrast to earlier studies, in this large contemporary cohort we showed no significant 
gender disparities in CVD risk associated with the development of T2DM. 
• Important sex differences in the management of risk factors remained: women with 
T2DM were more likely to be obese, have hypercholesterolemia and hypertension and 
were less likely to be prescribed statins and ACE inhibitors, especially if they had CVD. 
• In T2DM subgroups with CVD, women were less likely to receive antiplatelet agents 
than men. 
 
What are the clinical implications? 
• The observed gender biases in risk factor management highlight the need for closer 
adherence to prescribing guidance, continued routine surveillance for gender-related 
prescribing biases and possibly greater uptake of professional-based interventions in the 
community supporting the provision of high-quality equitable care. 
• Particular attention is required for women with abnormal cardiovascular risk factors, who 
may be receiving suboptimal preventative care. 
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Introduction  
Cardiovascular disease (CVD) is the leading cause of death in people with diabetes.1,2 Four large 
meta-analyses showed that after developing diabetes, the increase in the risk for fatal coronary 
heart disease, stroke or other atherosclerotic death was 27-50% higher for women than men.3–6 
The mechanism behind this sex disparity is still unclear but growing evidence suggests that the 
development of type 2 diabetes (T2DM) could adversely affect metabolic and CVD risk factor 
profiles more in women than men.7,8 Some of the excess risk observed in women could be 
explained by suboptimal and less aggressive CVD risk factor management, particularly after 
acute myocardial infarction;7–12 however, these previous studies lacked sufficient data to assess 
this.3–5  
 As the majority of studies examining  sex disparities in CVD risk in diabetes are now 
over a decade old (1960-2005)3–5, these estimates may not be relevant for contemporary practice. 
With a UK pay-for-performance scheme (Quality and Outcomes Framework; QOF) introduced 
in general practice in 2004 to improve diabetes care, the recording and monitoring of disease 
management has greatly improved over time and this is likely to have contributed to the year-on-
year reductions in risk for fatal and non-fatal CVD events.13–16 
 Our primary aim was to determine if sex disparities in CVD risk associated with T2DM 
are evident in a contemporary national cohort. Our secondary aim was to investigate the extent of 
any sex differences in the management of CVD risk factors and if these differences explain any 
disparities in CVD risk. Our hypotheses were that there would be no sex disparities in 
cardiovascular risk or risk factor management. 
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Methods 
Ethical Approval 
This study is based in part on data from the Clinical Practice Research Datalink obtained under 
licence from the UK Medicines and Healthcare products Regulatory Agency. The data is 
provided by patients and collected by the NHS as part of their care and support. ONS and HES 
data is subject to Crown copyright (2018) protection, re-used with the permission of The Health, 
& Social Care Information Centre, all rights reserved. The OPCS Classification of Interventions 
and Procedures, codes, terms and text is Crown copyright (2016) published by Health and Social 
Care Information Centre, also known as NHS Digital and licensed under the Open Government 
Licence available at www.nationalarchives.gov.uk/doc/open-government-licence/open-
government-licence.htm. The interpretation and conclusions contained in this study are those of 
the authors alone. The study was approved by the Independent Scientific Advisory Committee 
(ISAC) for CPRD research, ref. 15_123Mn.  
Data Sharing 
Read and ICD codes used are publicly available at The ClinicalCodes repository17 and can be 
accessed at  https://clinicalcodes.rss.mhs.man.ac.uk/. Electronic health records are, by definition, 
considered “sensitive” data in the UK by the Data Protection Act and cannot be shared via public 
deposition because of information governance restriction in place to protect patient 
confidentiality. Access to data is available only once approval has been obtained through the 
individual constituent entities controlling access to the data. The primary care data can be 
requested via application to the Clinical Practice Research Datalink (https://www.cprd.com); 
secondary care data can be requested via application to the hospital episode statistics from the 
UK Health and Social Care Information Centre (www.hscic.gov.uk/hesdata); and mortality data 
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are available by application to the UK Office for National Statistics 
(www.ons.gov.uk/ons/index.html). 
Data Source 
This retrospective population-based cohort study used data from the Clinical Practice Research 
Datalink (CPRD), an anonymised, longitudinal primary care medical record database of UK 
general practices.18 In 2015, the CPRD contained data on over 4.4 million active (alive, currently 
registered) patients from 674 registered general practices, equating to approximately 6.9% of the 
UK population.18 Patients are broadly representative of the general population in terms of age, 
sex, and ethnicity.18 The CPRD dataset was linked at the patient-level to hospitalisation data 
(Hospital Episode Statistics, HES), national mortality data (Office for National Statistics, ONS) 
and deprivation data, for all eligible patients in 380 linkage-consenting English practices. More 
detailed information on linkage is available in the Supplemental Methods.  
Study Population 
Incident T2DM cases were identified from Read codes in the electronic health record, if their 
first diagnostic code for diabetes (type 1 diabetes or type 2 diabetes) was recorded between 
01/01/2006-31/12/2013, with no diagnoses prior to this date. We used a validated algorithm to 
classify patients with T2DM based on diabetes codes, treatments, age, BMI and ethnicity.19 The 
application of this algorithm using CPRD data has been described previously.20 The index date in 
the T2DM cohort was defined as the first diagnostic code within the study window. 
 Patients with T2DM were matched (individual matching for categorical variables and 
caliper matching for continuous variables) with up to five controls without diabetes on year of 
birth (± 2 years), sex, and general practice. Patients with T2DM without any matched controls 
were excluded (6.9%). Individuals with T2DM and controls without diabetes were required to 
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have at least 1 year prior registration within the practice. All participants were observed from the 
index date to the endpoint date, study end date (31/03/2015), practice’s last data collection date, 
death, or transfer out of practice.  
 Figure 1 outlines the study populations included at each analytical phase. In phase 2, risk 
of incident major adverse cardiac events (MACE) associated with diabetes, individuals with a 
history of cardiovascular disease were excluded. In phase 3, management of risk factors in 
diabetes, all individuals diagnosed with type 2 diabetes (with or without a history of CVD) were 
included. 
Cardiovascular Outcomes 
The primary endpoint was the first record of the following major adverse cardiac events (MACE) 
after the diagnosis of diabetes, identified from primary care (Read codes), HES data (ICD-10 
codes) or ONS death data (ICD-10 codes): myocardial infarction (MI), stroke and cardiovascular 
death. Our secondary endpoints were: 1) fatal and non-fatal MI and 2) fatal and non-fatal stroke. 
Patient Demographics and Baseline Clinical Characteristics 
Ethnicity was identified from primary care records using Read codes and through linkage with 
HES as described previously.20 Deprivation data was defined using the Index of Multiple 
Deprivation (IMD) 2010 classification at the level of the patient’s residential postcode; 
categorised into five quintiles: IMD 1 (least deprived) to IMD 5 (most deprived). 
 Baseline data for obesity, HbA1c, blood pressure, hypercholesterolaemia (elevated total 
and LDL cholesterol), chronic kidney disease (stage 3 and above), microalbuminuria and 
proteinuria were captured as the closest measure up to 6 months before and 3 months after the 
index date (diabetes diagnosis date or corresponding date for controls). Further details on the 
definitions of these variables are provided in the Supplemental Methods. Cardiovascular disease 
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(including MI, coronary heart disease, stroke, transient ischaemic attack, peripheral vascular 
disease and cardiac arrest), neuropathy and retinopathy were defined using Read codes, up to the 
index date. Smoking status (current, former or never) was defined according to the closest 
recording before the index date.  
 Recorded HbA1c, blood pressure and cholesterol measurements were used to define risk 
factor control at baseline (further details are provided in the Supplemental Methods).  
Patient Management Variables 
To examine management in people with diabetes, we considered the frequency of risk factor 
checks, consultations with a healthcare professional within primary care, interventions offered 
and prescriptions for relevant medications. Risk factor observations included HbA1c tests, blood 
pressure checks, lipid checks, BMI measured and smoking cessation discussions recorded. 
Consultations were defined into two main categories: face-to-face interactions and telephone 
interactions with a healthcare professional. Interventions offered were classified into diet 
intervention, exercise intervention, structured education and bariatric surgery. Drug prescriptions 
included diabetes therapies, antihypertensive agents, lipid-lowering therapies and antiplatelet 
agents.  
 Patient management variables were assessed at yearly intervals after the diabetes 
diagnosis date (index date) until patients’ exit from study (end of follow-up). These data were 
summarised for the following time periods: year 1 (up to 3 months prior to and 12 months after 
the index date), years 2-3, years 4-5 and years 6-7. When patients had multiple measures 
recorded for biological variables within the time periods, the mean value was taken. 
Management variables were stratified and assessed by time-varying CVD status (with /without 
CVD during each follow-up time period). 
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Minimum Standard of Care Indicators for Diabetes  
Nine standards of care were considered based on QOF indicators for diabetes management in 
general practice between 2006 and 2013.21,22 The minimum standard of care indicators included: 
recording of BMI, HbA1c and blood pressure in the previous 15 months; testing for eGFR/serum 
creatinine and microalbuminuria in the previous 15 months; HbA1c, blood pressure and total 
cholesterol levels below specific targets in the previous 15 months; and treatment for 
microalbuminuria/proteinuria. 
 The indicators were assessed during the first 15 months of each follow-up time band 
following the diagnosis of diabetes (years 2-3, years 4-5 and years 6-7), in accordance with the 
QOF standards assessment period.  
Statistical Analysis 
Comparisons with T2DM and controls were sex-stratified for all analyses. In phase 1 of the 
study, baseline characteristics were summarised using mean (SD) and proportions as appropriate 
and comparisons by sex analysed using t-tests or chi-squared tests.  
 For phase 2, individuals with a history of cardiovascular disease at baseline were 
excluded. Stratified Cox proportional hazards models, accounting for the matched pairs (up to 
1:5 case control ratio) by allowing for distinct underlying hazard functions for each matched set 
(stratum), estimated sex-specific hazard ratios (HR) for the primary and secondary outcomes in 
people with type 2 diabetes compared to controls without diabetes. Four models were 
constructed: 1) unadjusted, 2) adjusted for baseline calendar year, age, general practice, 
ethnicity, and deprivation, 3) additional adjustments for baseline smoking, obesity, hypertension, 
hypercholesterolaemia and Charlson Comorbidity Index (excluding diabetes and cardiovascular 
conditions; see the Supplemental Methods and Supplemental Table 1 for further details) and 4) 
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adjustment for time-varying risk factors to capture intervention-related changes; smoking, 
obesity, hypertension, hypercholesterolaemia and raised HbA1c (>7% [53mmol/mol]). As 
additional covariates were adjusted for in the Cox models, inclusion of the matching factors in 
the models was required. The two-fold fully conditional specification algorithm for multiple 
imputation was used to impute longitudinal measurements for obesity, hypertension, 
hypercholesterolaemia and raised HbA1c (>7% [53 mmol/mol]); further details in the 
Supplemental Methods. The ratio of hazard ratios between women (DM vs. Non-DM) and men 
(DM vs. Non-DM) were calculated to estimate excess risk for CVD in women who developed 
diabetes compared to men who developed diabetes. The age-specific influence of diabetes on 
incident MACE events in women and men was estimated using unadjusted and multivariable-
adjusted Cox models stratified by age of onset of diabetes (<50, 50-60, 60-70, ≥70 years of age). 
As a sensitivity analysis, we compared risk estimates for diabetes diagnoses between an earlier 
and later time period (2007-2010 vs 2011-2013) within the study (further details in the 
Supplemental Material) and performed the unadjusted analysis on a prevalent type 2 diabetes 
cohort. 
 In phase 3, within the diabetes cohort alone, including those with and without prevalent 
CVD, management variables were summarised as percentages or age-adjusted rates and multiple 
logistic regression models assessed sex differences in attainment of standard of care indicators 
within follow-up time bands. As a sensitivity analysis, specific care indicators were stratified by 
CVD and age (details provided in the Supplemental Material).  
 Time with poor control was calculated as the time from the first risk factor measurement 
above a specified threshold until either: 1) the first subsequent measurement below the threshold, 
2) a change of drug regimen for the specific risk factor, or 3) end of follow-up; whichever came 
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first. For all drug therapies, the change in drug regimen was defined as the addition of a new 
drug to the current regimen and for diabetes medication this included adding insulin or switching 
to insulin. For each risk factor, sex-stratified cumulative incidence plots were constructed for the 
time from the risk factor level being above the cut-off to the time of drug intensification. The 
logrank test was used to determine if the probability of drug intensification occurring at any time 
point was significantly different in women and men; with a P-value<0.05 indicating a significant 
difference.  
 Finally, in patients with T2DM, we assessed sex differences in times to drug 
intensification after risk factor levels exceed specified thresholds. 
Analyses were performed using Stata 15.1 (StataCorp LP, College Station, TX). 
 
Results  
Phase 1: The cohort comprised of 79,985 patients with incident T2DM (44.3% women) and 
386,547 matched controls (44.8% women) with a mean ± SD follow-up of 3.6 ± 2.4 years and 
3.5 ± 2.4 years, respectively. Participant characteristics at baseline are presented in Table 1. At 
baseline, women with T2DM were 2-3 years older; more likely to be obese, have 
hypercholesterolaemia and chronic kidney disease than men with T2DM. Men with T2DM were 
more likely to be current smokers and have higher HbA1c, hypertension, and diabetes-related 
microvascular and macrovascular complications than women with T2DM. For both men and 
women with T2DM, those without CVD at the time of diabetes diagnosis had a worse risk factor 
profile than those with CVD, with a greater propensity for poorly-controlled HbA1c, 
hypertension and hypercholesterolaemia (Supplemental Table 2). Women with CVD at baseline 
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were approximately 4 years older than men with CVD and were more likely to have lower 
HbA1c levels, but higher cholesterol and established kidney disease (Supplemental Table 2). 
 Phase 2: During follow-up, MACE events occurred in 9,806 people with diabetes (12.3% 
overall; 11.6% of women and 12.8% of men) and 30,226 people without diabetes (7.8% overall; 
7.4% of women and 8.1% of men); Supplemental Table 3. In individuals without a previous 
history of cardiovascular disease, incident MACE events occurred in 4,564 people with diabetes 
(7.2% overall; 7.0% of women and 7.3% of men) and 11,665 people without diabetes (4.2% 
overall; 4.1% of women and 4.3% of men); Supplemental Table 3. The estimated hazard ratio of 
experiencing an incident MACE event associated with diabetes, after adjusting for baseline 
factors (non-modifiable and modifiable), was 1.23 (95% CI 1.16-1.32) for women and 1.17 
(1.11-1.23) for men, leading to a non-significant excess risk in women (relative risk ratio 1.05 
[95% CI 0.97-1.14]); Supplemental Table 4. After further adjusting for intervention-related 
changes in the modifiable risk factors in time-varying covariate-adjusted models, there remained 
no significant excess risk for MACE events in women compared to men (risk ratio: 1.07 [95% CI 
0.98-1.17]); Supplemental Table 4 and Figure 2. Similar findings were observed when stratified 
by year of T2DM diagnosis (Supplemental Tables 5 and 6). 
 We examined the interaction between ethnicity and gender on CVD risk, which was not 
significant (not shown). An inverse association between age of onset of diabetes and risk of 
incident MACE events in women and men was observed, with the highest risk in those 
diagnosed with type 2 diabetes aged 50 or younger; HR 2.83 (95% CI 1.86-4.30) in women and 
HR 2.18 (95% CI 1.73-2.74) in men (Supplemental Table 7). The magnitude of the excess risk 
for MACE events in women compared to men was similar across all age bands, except in those 
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aged over 70 where this attenuated; however, we did not identify any significant sex disparities 
in CVD risk within age groups (with the exception of those diagnosed with T2DM aged 60-70). 
 Phase 3: Within the diabetes cohort (with/without prevalent CVD at baseline and during 
follow-up), we assessed rates of risk factor checks and consultations, the proportions with risk 
factor levels above target levels and proportions prescribed various medications for abnormal 
risk factors in patients at specific time points from diagnosis (Supplemental Table 8). 
Management in men and women was broadly similar with some notable exceptions: a) compared 
to men, women had better glycaemic control; b) were more likely to be obese; c) have 
hypertensive end organ damage; and d) hypercholesterolaemia; but e) were less likely to be 
prescribed statin medication, despite having more frequent healthcare contacts.  
 Men and women without CVD at baseline or diagnosed during follow-up were 
consistently more likely to be obese, have poorer glycaemic control, hypertension, 
hypercholesterolaemia, and substantially lower prescribing of antihypertensive agents, 
antiplatelets and lipid-lowering medications than those with CVD (Supplemental Tables 9 and 
10). Within patients without CVD, sex differences were observed with women more likely to 
have hypercholesterolaemia but with fewer prescriptions for lipid-lowering medications than 
men (Supplemental Table 10). In those with CVD at diagnosis or diagnosed during follow-up, 
the proportion of women receiving statins, antiplatelet medications and the majority of 
antihypertensive drugs (with the exception of ARIIBs and diuretics) was lower compared to men 
(Supplemental Table 9).  
 Performance against nine minimum care standards was assessed at different time 
intervals from the diabetes diagnosis (Supplemental Table 11). The proportion of women and 
men meeting each standard of care were comparable with a few exceptions in keeping with the 
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above analysis: a) women were less likely than men to have a total cholesterol ≤ 5 mmol/l; and 
b) were less likely to be prescribed ACE inhibitors in the presence of proteinuria or 
microalbuminuria (Supplemental Table 11); c) women were also less likely than men to be 
prescribed statins (Supplemental Table 12). Sex differences in achieved cholesterol levels and 
treatment with statins were more obvious in those with prevalent CVD compared to those 
without CVD (Supplemental Tables 11 and 12) and especially in younger patients (Supplemental 
Table 12).  
 Finally, in patients with T2DM, we assessed sex differences in times to drug 
intensification after risk factor levels exceed specified thresholds. These data indicated only 
modest sex differences in times to drug intensification (Figure 3; Supplemental Table 13): a) 
women with hypertension taking 0 or 1 antihypertensive agents were treated up to 1 month 
earlier than men on the same drug regimen. However, this modest early effect was not reflected 
in the probability of treatment intensification over 7 years (Supplemental Table 13) or when 
considering all hypertensive patients over the entire follow-up period (Figure 3); b) women with 
hypercholesterolemia and CVD were 10% less likely to be prescribed lipid lowering medication 
Supplemental Table 13); c) there were no sex-related differences in the intensification of 
treatment for hyperglycaemia (Figure 3 and Supplemental Table 13).  
 
Discussion  
In contrast to findings from earlier studies, in this large contemporary primary care-based cohort 
study in England, we found that women who developed T2DM did not have a significantly 
higher relative increase in their risk for CVD than men who develop T2DM, before or after 
adjusting for non-modifiable and modifiable risk factors. However, some important sex 
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differences in the management of risk factors were observed. From onset of diabetes and in the 
subsequent years, compared to men with T2DM, women with T2DM had better glycaemic 
control but were more likely to have obesity, hypercholesterolaemia and hypertension and less 
likely to be prescribed lipid-lowering medication and ACE inhibitors, especially if they had 
CVD. In the T2DM subgroup, those without CVD at baseline or throughout follow-up 
consistently had worse risk factor control than those with CVD but had lower prescribing of 
antihypertensive agents, antiplatelets and lipid-lowering medications. In both subgroups with and 
without CVD, women were less likely to receive antiplatelet medications than men. 
Prior studies of sex disparities in CVD risk associated with developing type 2 diabetes 
Prior meta-analyses have shown that after developing diabetes, the increase in risk for fatal 
coronary heart disease, stroke or other atherosclerotic death was higher for women than men - 
with significant ratios of relative risks: 1.46 (95% CI: 1.14-1.88) for fatal coronary heart 
disease;5 1.44 (1.27-1.63) for incident coronary heart disease;3 1.27 (1.10-1.46) for stroke4; and 
1.43 (1.27-1.61) for all fatal atherosclerotic disease.6 Although these meta-analyses included a 
large number of observational studies (n=37-68),3–6 these cohorts covered a much earlier era 
(approximate data collection: 1981-19953, 1983-19974, 1980-19925, and 1985-20026) when there 
may have been less emphasis on CVD risk reduction in clinical practice. Of the most recent 
CVD risk estimates from an English cohort, women were reported to have a higher risk for 
myocardial infarction after developing diabetes than men but there were no sex differences for 
other cardiovascular outcomes.23 
 One potential explanation for these changing findings over time may be that less 
emphasis was placed on CVD risk in women with diabetes than in men.24–26 Our study uses 
contemporary data reflecting very recent clinical practice in the England where the quality and 
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equity of care may have been positively influenced by recent UK management guidelines16 and 
the QOF, a pay-for-performance initiative standardising service improvements in primary care.13  
 We observed that the risk of MACE was approximately 40% higher in people with 
T2DM compared to the general population (Figure 2), whereas prior studies have indicated a 2-
3-fold higher risk associated with diabetes.3–6 The lower relative risks observed in our study may 
result from differences in the study populations. We identified community-based patients with 
incident type 2 diabetes undergoing contemporary CVD risk management who are likely to have 
lower CVD risks than many described in the prior literature.3–6 For example, prior studies 
included: a) people from ethnic groups with high CVD risk (e.g. Pima Indians and Pacific 
Islanders including Melanesian and Indian Fijians); b) those with prevalent diabetes patients; c) 
younger populations (<50 years) in whom relative risks associated with diabetes may be higher 
as indicated in Supplemental Table 7; and d) higher risk people from outside of primary care 
settings. As a sensitivity analysis, we performed an unadjusted analysis on a prevalent T2DM 
cohort (Supplemental Table 14). Compared to people without diabetes, the hazard ratios for 
MACE, MI and stroke events in the prevalent cohort were numerically higher for both women 
and men than in the incident cohort. However, the ratio of risks between women and men with 
type 2 diabetes were comparable and were not statistically different. 
Sex disparities in risk factors 
Historically, it has been thought that men with diabetes were diagnosed at an earlier age, were 
treated more actively, and were more likely to achieve recommended risk factor levels compared 
to women with diabetes.11,27 The UK National Diabetes Audit of nearly 2 million people studied 
between 2012 and 2013, showed that 58% of women and 62% of men received recommended 
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care processes, and that 34% of women and 37% of men achieved treatment targets for HbA1c, 
blood pressure and cholesterol.28  
 In our cohort, men were diagnosed about 2.6 years earlier than women and generally 
CVD risk factor management was worse in women compared to men, with the exception of 
glycaemic control. It is known that at the diagnosis of type 2 diabetes, women have higher levels 
of BMI than men.7 The higher BMI levels in women could have a role in causing endothelial 
dysfunction, hypertension, dyslipidaemia and abnormalities in fibrinolysis and thrombosis that 
contribute to CVD risk.8,29,30  
Sex disparities in prescribing 
The most notable gender disparities in prescribing were in relation to treatment with statins, ACE 
inhibitors and aspirin and we showed that these differences were only in part explained by 
avoidance of these medications in pre-menopausal women, in accordance with recommended 
guidelines (Supplemental Table 12).31,32 As those aged<50 accounted for only 17% of the total 
population of women at baseline, this should not have heavily impacted on the disparities we 
observed between men and women. Furthermore, the probability of lipid-lowering therapy 
initiation and escalation in those with hypercholesterolaemia was significantly lower in women, 
particularly so in those with CVD, a finding which has been observed previously.11 The 
explanation behind lower prescribing in women with CVD than men with CVD is difficult to 
determine from these data and may be multifaceted. Potential explanations include: sex-related 
prescribing biases in physicians, sex-related differences in symptoms caused by coronary heart 
disease, or sex-related differences in patient attitudes and beliefs about their health status and 
requirement for medications. Further research is needed to better understand these findings.  
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Strengths and limitations 
This study has several important strengths: First, we undertook a large retrospective population-
based study using primary care data linked to hospital and mortality records allowing us to assess 
gender-related differences in CVD events, mortality, consultations and risk factor management 
associated with type 2 diabetes. Second, we used an incident cohort, which reflects contemporary 
practice and avoids the distorting influences of survival bias present in a prevalent cohort. Third, 
there were sufficient numbers of events to exclude clinically significant CVD risk differences 
between men and women developing diabetes and we were able to make meaningful 
comparisons of CVD risk factor management for up to 7 years following diagnosis.  
 We acknowledge some limitations: First, there was a relatively high proportion of 
missing data in non-diabetic controls for a number of CVD risk factors, along with missing data 
in the diabetes group; however we addressed this by performing multiple imputation using a 
number of clinical characteristics to provide appropriate estimates within these populations. The 
proportion of missing data was similar in men and women with or without diabetes. Therefore, 
this should not have heavily influenced estimates of CVD risk differences in men and women 
with diabetes. Furthermore, in accordance with previous observational evidence, an attenuation 
in the effect of diabetes with age on CVD risk was observed in both men and women 
(Supplemental Table 7) providing further reassurance of the robustness of this data.33–35 Second, 
our cohort, constructed with individuals with newly-diagnosed type 2 diabetes between 2006 and 
2013, may limit comparisons with prior work that included individuals with prevalent diabetes. 
An incident cohort was sought as UK-wide changes to improve diabetes care were introduced 
over 2004-6 through the Quality and Outcomes Framework (QOF); therefore, prevalent diabetes 
diagnosed prior to this time could have distorted our findings. Furthermore, there are important 
D
ow
nloaded from
 http://ahajournals.org by on April 16, 2019
10.1161/CIRCULATIONAHA.118.039100 
19 
issues around survival bias with prevalent cases. It is a strength that our incident cohort reflects 
contemporary clinical management practice.  Third, cohort characteristics and more active 
management of CVD risk in our contemporary cohort may explain the lower CVD risk 
associated with diabetes compared to more historical reports as described above. Fourth, the 
analyses based on patients assessed at fixed times following diagnosis (Supplemental Tables 8, 9 
and 10) do not account for deaths and dropouts; however, loss to follow-up is unlikely to be 
strongly gender-related. Furthermore, data on CVD management was limited for years 6-7 years 
post-diagnosis due to the smaller sample size with longer follow-up; the average duration of 
follow-up was 3.6±2.4 years, explained by CVD and mortality events, patients entering the 
cohort later and cohort attrition. Finally, the analysis is based on data from English general 
practices and so generalisation to other healthcare systems may be limited. The sex disparity in 
cholesterol control and lipid-lowering prescribing observed in this study have been observed in 
other diabetes populations;36–38 however, comprehensive longitudinal studies of all aspects of 
type 2 diabetes care in different countries are needed to evaluate the full extent of any current sex 
disparities in treatment and management.  
Clinical implications 
Reassuringly, we showed that the previously reported gender disparities in CVD risk associated 
with T2DM are not evident in contemporary English general practice. However, the observed 
gender biases in risk factor management highlight the need for closer adherence to clinical 
guidance for drug therapy, continued routine surveillance for gender-related prescribing biases 
and possibly greater uptake of professional-based interventions in the community to support the 
provision of equitable care.39,40 Particular attention is required for high-CVD risk women without 
established CVD, who may not be receive optimal preventative care. 
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Conclusions 
Whilst there is clear improvement in the relative risks for CVD events, sex disparities in the 
management of CVD risk factors should prompt renewed efforts to improve the standard and 
equity of diabetes care for women and men with diabetes. 
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Table 1. Baseline clinical characteristics of patients with incident type 2 diabetes (T2DM) and matched 
controls without diabetes  
 
 T2DM (N=79,985) Controls (N=386,547) 
Women Men Women Men 
n, % 35,396 (44.3) 44,589 (55.8) 172,994 (44.8) 213,553 (55.3) 
Age, years 63.9±14.3 61.3±13.0 63.7±14.4 60.8±13.0 
Ethnicity     
White 28,090 (79.4) 34,251 (77.4) 127,344 (73.6) 145,259 (68.0) 
South Asian 1,544 (4.4) 1,792 (4.0) 2,960 (1.7) 3,357 (1.6) 
Black 784 (2.2) 748 (1.7) 2,226 (1.3) 2,223 (1.0) 
Other 400 (1.1) 507 (1.1) 1,545 (0.9) 1,8012 (0.8) 
Unknown 4,578 (12.9) 7,021 (15.8) 38,919 (22.5) 60,913 (28.5) 
Deprivation     
IMD 1 (least deprived) 6,330 (17.9) 8,810 (19.8) 37,354 (21.6) 48,7132 (22.8) 
IMD 2 7,624 (21.5) 10,225 (22.9) 40,447 (23.4) 50,231 (23.5) 
IMD 3 7,063 (20.0) 9,039 (20.3) 34,934 (20.2) 42,807 (20.1) 
IMD 4 7,614 (21.5) 8,961 (20.1) 33,356 (19.3) 39,8665 (18.7) 
IMD 5 (most deprived) 6,708 (19.0) 7,510 (16.8) 26,698 (15.4) 31,667 (14.8) 
Unknown 57 (0.2) 44 (0.1) 205 (0.1) 269 (0.1) 
Obese 18,517 (52.3) 22,011 (49.4) 17,815 (10.3) 18,758 (8.8) 
Smoking     
Current 11,203 (31.7)  20,883 (46.8) 45,309(26.2) 72,517 (34.0) 
Ex-smoker 9,923 (28.0) 11,564 (25.9) 47,009 (27.2) 59,265 (27.8) 
Never  1,992 (5.6) 1,468 (3.3) 9,489 (5.5) 7,669 (3.6) 
Unknown 12,278 (34.7) 10,674 (23.9) 71,187 (41.2) 74,102 (34.7) 
HbA1c >7% (53mmol/mol) 15,819 (44.7) 21,867 (49.0) - - 
HbA1c >8% (64mmol/mol) 8,844 (25.0) 13,599 (30.5) - - 
BP>140/80 mmHg 10,683 (30.2) 14,199 (31.8) 18,142 (10.5) 18,768 (8.8) 
BP>130/80 mmHg 15,577 (44.0) 19,638 (44.0) 26,636 (15.4) 26,737 (12.5) 
with target organ damage 4,537 (12.8) 3,660 (8.2) 9,393 (5.4) 6,856 (3.2) 
Hypercholesterolaemia* 8,973 (25.4) 10,244 (23.0) 5,357 (3.1) 5,958 (2.8) 
Risk factors in control †     
1 Risk factor in control 14,617 (41.3) 17,531 (39.3) 154,999 (89.6) 195,919 (91.7) 
2 Risk factors in control 4,815 (13.6) 5,813 (13.0) 17,693 (10.2) 16,861 (7.9) 
3 Risk factors in control 503 (1.4) 820 (1.8) 302 (0.2) 773 (0.4) 
Cardiovascular Disease     
Coronary heart disease 3,910 (11.1) 7,506 (16.8) 10,767 (6.2) 20,096 (9.4) 
Cerebrovascular disease 2,175 (6.1) 2,737 (6.1) 7,563 (4.3) 9,369 (4.4) 
Peripheral vascular disease 946 (2.7) 1,808 (4.1) 2,631 (1.5) 4,813 (2.3) 
Chronic kidney disease 7,921 (22.4) 5,974 (13.4) 21,238 (12.3) 16,162 (7.6) 
Microalbuminuria or proteinuria 3,416 (9.7) 5,923 (13.3) 2,735 (1.6) 3,726 (1.7) 
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Peripheral neuropathy 343 (1.0) 527 (1.2) 565 (0.3) 789 (0.4) 
Retinopathy 1,278 (3.6) 1,825 (4.1) 25 (0.01) 23 (0.01) 
History of pregnancy 10,312 (29.1) - 50,399 (29.1) - 
Hormone-replacement therapy 
(current use) ‡ 
451 (1.3) - 3,079 (1.8) - 
Oral contraceptives (current use) ‡ 397 (1.1) - 1,380 (0.8) - 
Data presented as N (%) or mean±SD     
* total cholesterol>4mmol/L or LDL cholesterol>2mmol/L  
† HbA1c <7% (53mmol/mol); BP < 130/80mmHg; lipids: total cholesterol<4mmol/L or LDL 
cholesterol<2mmol/L  
‡ Current use defined as prescriptions up to 90 days prior to index date 
% missing data in T2DM: Obesity 12.2% (women 12.8%, men 11.7%), HbA1c 17.8% (women 17.8%, men 
17.8%), Blood Pressure 29.5% (women 28.7%, men 30.1%), Hypercholesterolaemia 65.8% (women 66.7%, 
men 65.1%), Microalbuminuria/Proteinuria 46.1% (women 46.7%, men 45.5%).  
% missing data in Controls: Obesity 66.5% (women 63.4%, men 69.0%), HbA1c 97.8% (women 97.7%, 
men 97.9%), Blood Pressure 77.5% (women 74.5%, men 79.9%), Hypercholesterolaemia 96.3% (women 
96.4%, men 96.2%), Microalbuminuria/Proteinuria 92.4% (women 91.4%, men 93.2%) 
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Figure Legends 
Figure 1. Definition of cohorts across study phases 
Figure 2. Unadjusted and multivariable-adjusted hazard ratios for incident CVD 
comparing people with and without T2DM by sex, and ratio of risk (RRR) for women 
relative to men  
Adjusted for age, ethnicity, deprivation, general practice, calendar year, baseline: smoking, 
obesity, hypertension, hypercholesterolaemia, comorbidities and time-varying: smoking, obesity, 
hypertension, hypercholesterolaemia, raised HbA1c. 
 Ratio of relative risks (RRR) greater than 1 indicates an excess risk for incident CVD in women 
who developed diabetes compared to men who developed diabetes. 
CVD indicates cardiovascular disease; T2DM, type 2 diabetes; MACE, major adverse cardiac 
events; MI, myocardial infarction; HR, hazard ratio; CI, confidence interval. 
Figure 3. Comparison of the proportion of men and women undergoing intensification of 
drug regimens in relation to the time that their risk factors (HbA1c, BP, lipids) were above 
threshold values: A) HbA1c >7% (53mmol/mol); B) BP >140/80 mmHg in patients with 
prevalent CVD, C) LDL-cholesterol >2 mmol/L or total cholesterol >4 mmol/L in patients 
with prevalent CVD, D) LDL-cholesterol >2 mmol/L or total cholesterol >4 mmol/L in 
patients without prevalent CVD 
BP indicates blood pressure; LDL-C, low-density lipoprotein cholesterol; TC, total cholesterol; 
CVD, cardiovascular disease. 
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Phase 1: Clinical characteristics of type 2 diabetes patients and matched controls 
    Individuals with incident  
 type 2 diabetes (N=79,985) 
 Individuals without diabetes 
(N=386,547) 
Inclusion criteria: 
i. First diagnosis of diabetes (type 1 diabetes 
or type 2 diabetes) recorded between 1 
January 2006 and 31 December 2013 (index 
date). Algorithm applied to classify those 
with type 2 patients  
 
ii. Must have at least 1 year prior  
registration at current practice 
 
iii. Practice and individual’s data meeting 
CPRD “up to standard” criteria for research 
 
iv. Eligible for linkage to Hospital Episode 
Statistics (HES), Office for National Statistics 
mortality data and deprivation data 
Inclusion criteria: 
i. No record of any type of diabetes 
 
ii. Must have at least 1 year prior 
registration at current practice 
 
iii. Practice and individual’s data 
meeting CPRD “up to standard” 
criteria for research 
 
iv. Eligible for linkage to Hospital 
Episode Statistics (HES), Office for 
National Statistics mortality data and 
deprivation data 
 
 
People with diabetes were matched to up to 5 people without diabetes (N=386,547) on year of birth 
(± 2 years), sex, and general practice.  
Phase 2: Major cardiovascular event (MACE) risk associated with diabetes, by sex 
 
Individuals with prevalent cardiovascular disease were excluded 
 
Type 2 diabetes (N=63,718; 29,348 (46.1%) women and 34,370 (53.9%) men) and 
 Controls (N=277,176; 130,524 (47.1%) women and 146,652 (52.9%) men) 
 
MACE defined as fatal/non-fatal myocardial infarction, fatal/non-fatal stroke and 
cardiovascular death. 
Individuals observed from the index date to the MACE endpoint date, study end date (31 
March 2015), practice’s last data collection date, death, or transfer out of practice.  
Maximum follow-up of 9 years. 
Phase 3: Sex associated cardiovascular risk factor management in type 2 diabetes  
 
Individuals with prevalent cardiovascular disease were included 
 
Type 2 diabetes (N=79,985) 
Women (n=35,396; 44.3%); Men (n=44,589; 55.8%) 
 
Risk Factors, clinical characteristics and patient management data captured during 
follow-up time bands after diabetes diagnosis; Year 1 (-3 months to +12 months), Years 
2-3, Years 4-5, Years 6-7. Follow-up time captured during Phase 2. 
Minimum Standard of Care Indictors for diabetes captured during follow-up time bands 
from Years 2-3.  
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Time from LDL-C or TC above cut-off  (years) 
Time from HbA1c above cut-off  (years) 
A B 
D C 
Time from BP above cut-off  (years) 
Time from LDL-C or TC above cut-off  (years) 
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